Find company research, competitor information, contact details & financial data for Affibody AB of Solna, Stockholm. Get the latest business insights from Dun

Affibody will be responsible for the manufacturing and supply of ABY-035 for development and commercialization worldwide and is not precluded from additional collaboration and licensing agreements in territories not covered by this agreement. About ABY-035. Currently in Phase 2 development, ABY-035 is an innovative fusion protein targeting IL-17.

2010-06-18 · Affibody molecules can also block soluble protein ligands as exemplified with a TNFα specific Affibody molecule that could block binding of the TNF ligand to the TNF-receptor , in in vitro studies. An interesting case is an Affibody molecule specific for the amyloid-β (Aβ) peptide involved in Alzheimer’s disease [72] . Affibody将负责为ABY-035在全球的临床开发和商业化进行药品的生产和供应。 ABY-035是抑制白介素17的新型融合蛋白药物，即将完成全球临床二期。ABY-035利用Affibody独创的、具有全球专利的两大技术平台 “Affibody技术平台” 和 “Albumod技术平台” 开发而成。 Affibody molecules can be engineered in different formats. (a) and the molecule wa s named ABY-035 and ha s entered clinic al. developmen t.

A number of HER3-targeting monoclonal antibodies are under clinical investigation as potential cancer therapeutics. Smaller high-affinity scaffold proteins are attractive non-Fc containing alternatives to antibodies. A previous study indicated that anti-HER3 affibody Inmagene and Affibody have formed a strategic partnership to develop and commercialize izokebep (IMG-020 or ABY-035), a bispecific fusion protein targeting Interleukin-17A, for multiple auto-immune indications worldwide. Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced positive top-line data from its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035 in patients with moderate-to-severe psoriasis (“AFFIRM-35”).

Solna, Sweden, May 4, 2016. Affibody AB (“Affibody”) today announced that it has completed the dose-escalation part of a Phase I study of ABY-035, which is the company’s proprietary psoriasis program. Initial results confirm compound to be safe and well-tolerated across all doses in healthy volunteers.

About ABY-035. Currently in Phase 2 development, ABY-035 is an innovative fusion protein targeting IL-17. Affibody: ClinicalTrials.gov Identifier: NCT04706741 Other Study ID Numbers: ABY-035-203 : First Posted: January 13, 2021 Key Record Dates: Last Update Posted: January 19, 2021 Last Verified: December 2020 Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that the U.S. FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA).

Affibody har meddelat positiva topline-data från fas II-studien med ABY-035 i patienter med psoriasis. Läs mer. Bolaget har även meddelat att

Solna, Sweden, February 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of enrollment in the Company’s Phase 2 proof-of-concept study of ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).

2017-03-24 · Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. ABY-035 is being evaluated in patients with plaque psoriasis. Affibody: ClinicalTrials.gov Identifier: NCT03580278 Other Study ID Numbers: ABY-035-101 : First Posted: July 9, 2018 Key Record Dates: Last Update Posted: November 30, 2020 Last Verified: November 2020 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Affibody: ClinicalTrials.gov Identifier: NCT04713072 Other Study ID Numbers: ABY-035-202 : First Posted: January 19, 2021 Key Record Dates: Last Update Posted: January 20, 2021 Last Verified: January 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Solna, Sweden, November 10, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced the initiation of its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035 in patients with psoriatic arthritis (PsA). Affibody and Inmagene Biopharmaceuticals has announced that the FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA). Affibody Announces Initial Results from a Phase I Study of ABY-035 Solna, Sweden, May 4, 2016.
Sen anmalan antagning

Solna, Sweden, June 15, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today announced positive top-line data from its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035 in patients with moderate-to-severe psoriasis (“AFFIRM-35”). Solna, Sweden, July 16, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of the planned 12 week interim analysis in the Company’s Phase 2 proof-of-concept study of its bispecific molecule ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).

The company has completed a planned 12 week interim analysis in the its Phase 2 proof-of-concept study of its bispecific molecule ABY-035 for moderate-to-severe psoriasis (“AFFIRM 35”). “Our Phase 2 AFFIRM-35 study with ABY-035 has now reached the stage where we are starting to see the first results,” said David Bejker, CEO of Affibody. Affibody: ClinicalTrials.gov Identifier: NCT03591887 Other Study ID Numbers: ABY-035-002 2017-001615-36 ( EudraCT Number ) First Posted: July 19, 2018 Key Record Dates: Last Update Posted: July 10, 2020 Last Verified: July 2020 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Affibody secures production capacity for ABY-035.
Moms deklaration enskild firma blankett

Affibody AB (“Affibody”), a clinical stage biopharmaceutical company, today process development and GMP manufacturing of Affibody's ABY-035 drug.

That construct is coupled to a third component, Albumod, Affibody’s small albumin-binding domain, which extends the molecule’s half-life. “ABY-035 is a unique multivalent and bispecific molecule, targeting both subunits of IL-17 as well as albumin and the Phase 2 AFFIRM-35 study is designed to take full advantage of the strengths of the dual targeting ABY-035. Affibody, a clinical stage biopharmaceutical company, today announced positive top-line data from its 52-week trial investigating the novel bispecific IL-17A inhibitor ABY-035 in patients with moderate-to-severe psoriasis (“AFFIRM-35”). SAN DIEGO, CA, USA; SHANGHAI, China, and SOLNA, Sweden I February 10, 2021 I Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that the U.S. FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA).

Affibody is a Swedish biotech company focused on developing products for therapy, diagnostic imaging, and other applications.

ABT-165 (AbbVie). 6.7.

The subjects will be followed for pharmacokinetic and safety assessments up to Day 95 after dosing. Part B of the study consists of 6 healthy volunteers who will be given a single subcutaneous dose of ABY-035. 1. Evaluate safety, tolerability of ABY-035 2.